insulin aspart · NovoLog

Peptide

Approved / Phase 4Insulin receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
EU
  • Diabetes mellitus (NovoRapid, Novo Nordisk A/S)
Product first approved 1999EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (66)
Type 1 Diabetes
NCT03377699 · Novo Nordisk A/S
2017-11-22 – 2020-12-17 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT03874715 · Sanofi
2019-03-11 – 2020-07-08 · Type 1 Diabetes Mellitus
What this study did
NCT04079413 · Geropharm
2019-06-03 – 2020-01-21 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02034513 · Novo Nordisk A/S
2014-01-05 – 2016-01-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01513473 · Novo Nordisk A/S
2012-01-16 – 2013-07-30 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01079234 · Novo Nordisk A/S
2010-03 – 2011-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01074268 · Novo Nordisk A/S
2010-02 – 2010-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00982228 · Novo Nordisk A/S
2009-09-01 – 2010-11-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00474045 · Novo Nordisk A/S
2007-05 – 2010-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00978627 · Novo Nordisk A/S
2009-08 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00623194 · Novo Nordisk A/S
2008-02 – 2009-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00435019 · Novo Nordisk A/S
2007-02 – 2008-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00447382 · Novo Nordisk A/S
2007-03 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00184665 · Novo Nordisk A/S
2004-06 – 2006-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00095082 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00725036 · Novo Nordisk A/S
2002-09-02 – 2004-12-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00595374 · Novo Nordisk A/S
2003-12-02 – 2004-10-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00604656 · Novo Nordisk A/S
2003-05-05 – 2004-01-29 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312156 · Novo Nordisk A/S
2002-08 – 2003-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312104 · Novo Nordisk A/S
2002-04 – 2003-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00832182 · Novo Nordisk A/S
1999-12-22 – 2002-11-25 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01697657 · Novo Nordisk A/S
2001-09 – 2002-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01486940 · Novo Nordisk A/S
2002-03 – 2002-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01707134 · Novo Nordisk A/S
1997-09 – 2000-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT05802862 · Sunshine Lake Pharma Co., Ltd.
2023-07-06 – 2024-08-16 · Diabetes
What this study did
NCT04226105 · Geropharm
2020-01-20 – 2020-12-25 · Diabetes Mellitus, Type 2, Diabetes Mellitus
What this study did
NCT02762578 · Novo Nordisk A/S
2016-05-03 – 2017-06-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01023165 · Global Infusion and Aspiration Systems, LLC
2009-11 – 2015-11 · Diabetes Mellitus, Metabolic Integrity
What this study did
NCT01474538 · Eli Lilly and Company
2011-12 – 2013-02 · Type 2 Diabetes Mellitus
What this study did
NCT01513590 · Novo Nordisk A/S
2012-01-16 – 2012-11-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01388361 · Novo Nordisk A/S
2011-09 – 2012-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01365507 · Novo Nordisk A/S
2011-06 – 2012-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01272193 · Novo Nordisk A/S
2011-01 – 2011-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00151697 · Rijnstate Hospital
started 2005-05 · Diabetes Mellitus Type II
What this study did
NCT01059812 · Novo Nordisk A/S
2010-02-01 – 2010-12-23 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00972283 · Novo Nordisk A/S
2009-09-01 – 2010-10-28 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01045707 · Novo Nordisk A/S
2010-01 – 2010-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01045447 · Novo Nordisk A/S
2010-01 – 2010-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01009580 · Novo Nordisk A/S
2009-11-05 – 2010-08-23 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00313001 · Novo Nordisk A/S
2006-04 – 2007-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00318786 · Novo Nordisk A/S
2006-04 – 2007-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00504673 · Novo Nordisk A/S
2005-04 – 2006-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (6)
Type 1 Diabetes
NCT03262116 · Massachusetts General Hospital
2019-03-19 – 2019-07-23 · Type 1 Diabetes Mellitus
What this study did
NCT03565666 · Massachusetts General Hospital
2018-07-09 – 2018-11-19 · Type1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT00228904 · Florida Atlantic University
2005-02 – 2011-10 · Diabetic Neuropathy
What this study did
Other / comorbidity
NCT02496780 · University of Minnesota
2015-08 – 2022-07 · Cystic Fibrosis
What this study did
NCT00539409 · Florida Atlantic University
2006-11 – 2009-08 · Diabetes Mellitus, With Complications
What this study did
NCT01029639 · Florida Atlantic University
2007-01 – 2009-08 · Hypoglycemia
What this study did
Phase 2 (13)
Type 1 Diabetes
NCT02509429 · University Hospital, Montpellier
2015-06-16 – 2016-12 · Type 1 Diabetes
What this study did
NCT02416765 · Institut de Recherches Cliniques de Montreal
2015-05 – 2015-10 · Type 1 Diabetes
What this study did
NCT01194245 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type 1
What this study did
NCT00841087 · Novo Nordisk A/S
2009-01 – 2009-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00612040 · Novo Nordisk A/S
2008-01 – 2008-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06558708 · Gan and Lee Pharmaceuticals, USA
2024-06-28 – 2024-12 · Type 2 Diabetes
What this study did
NCT01510093 · Aarhus University Hospital
2012-05 – 2013-01 · Type 2 Diabetes Mellitus
What this study did
NCT01194258 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type II
What this study did
NCT00842361 · Novo Nordisk A/S
2009-01 – 2009-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00613951 · Novo Nordisk A/S
2008-01 – 2008-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00614055 · Novo Nordisk A/S
2008-01 – 2008-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04292535 · Michigan State University
2018-06-15 – 2020-02-20 · Insulin, Exercise
What this study did
NCT01561378 · Albert Einstein College of Medicine
2012-08 – 2014-10 · Post-operative Cognitive Decline, Post-operative Delirium
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT00581867 · Jeff Burns, MD
2007-10 – 2012-05 · Alzheimer's Disease
What this study did
NCT00353990 · University of Aarhus
2006-08 – 2006-12 · Diabetes Mellitus
What this study did
Phase 1 (56)
Type 1 Diabetes
NCT06809621 · Novo Nordisk A/S
2025-01-29 – 2025-07-28 · Diabetes Mellitus, Type 1
What this study did
NCT03666065 · Yale University
2020-01-01 – 2023-06-30 · Type1diabetes
What this study did
NCT03436498 · Sanofi
2018-05-10 – 2018-10-06 · Type 1 Diabetes Mellitus
What this study did
NCT02612844 · Novo Nordisk A/S
2015-11 – 2016-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT02059174 · Merck Sharp & Dohme LLC
2014-02-10 – 2015-04-27 · Type 1 Diabetes Mellitus
What this study did
NCT01773798 · Novo Nordisk A/S
2013-01 – 2013-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01590836 · Novo Nordisk A/S
2012-04 – 2012-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01455142 · Novo Nordisk A/S
2011-10 – 2012-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01399346 · Medical University of Graz
2011-04 – 2011-06 · Type 1 Diabetes
What this study did
NCT01269606 · Novo Nordisk A/S
2011-01 – 2011-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01173926 · Novo Nordisk A/S
2010-07 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01174303 · Novo Nordisk A/S
2010-08 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01138488 · Novo Nordisk A/S
2010-06 – 2010-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01051102 · Novo Nordisk A/S
2010-01 – 2010-04 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01464099 · Novo Nordisk A/S
2008-06 – 2008-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01868568 · Novo Nordisk A/S
2008-04 – 2008-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01536028 · Novo Nordisk A/S
2006-04 – 2006-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT07068295 · Novo Nordisk A/S
2025-07-11 – 2026-03-10 · Diabetes Mellitus, Type 2
What this study did
NCT05754424 · Arecor Limited
2023-02-27 – 2024-02-12 · Diabetes Mellitus, Type 2
What this study did
NCT01134224 · Novo Nordisk A/S
2010-05 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01028404 · Novo Nordisk A/S
2009-11 – 2010-06 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00184613 · Novo Nordisk A/S
2005-05 – 2006-01 · Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
What this study did
NCT00115973 · Novo Nordisk A/S
2005-06 – 2006-01 · Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
What this study did
Other / comorbidity
NCT05946798 · Anna Stanhewicz, PhD
2023-08-30 – 2028-06-01 · Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
What this study did
NCT06547619 · Anna Stanhewicz, PhD
2024-10-01 – 2027-05 · Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
What this study did
NCT07918898 · Gan & Lee Pharmaceuticals.
2026-11-02 – 2027-02-02 · Healthy Participants
What this study did
NCT06375031 · Jiangsu HengRui Medicine Co., Ltd.
2024-05 – 2024-07-15 · Diabetes
What this study did
NCT05737576 · Jiangsu HengRui Medicine Co., Ltd.
2023-03-20 – 2023-12-08 · Diabetes
What this study did
NCT05104424 · Ministry of Health, Saudi Arabia
2021-12-26 – 2022-10-01 · Smell Dysfunction, Taste Disorders, Taste Disorder, Secondary, Sweet, Taste Disorder, Secondary, Bitter, Smell Disorder
What this study did
NCT04660305 · Arecor Limited
2020-12-02 – 2021-06-11 · Diabetes Mellitus, Type 1
What this study did
NCT04237129 · Gan and Lee Pharmaceuticals, USA
2019-08-27 – 2019-12-16 · Diabetes Mellitus, Type 1
What this study did
NCT02462161 · Wake Forest University Health Sciences
2015-03-20 – 2019-04-16 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did
NCT02844790 · Novo Nordisk A/S
2016-07-26 – 2016-09-27 · Healthy
What this study did
NCT02594033 · Novo Nordisk A/S
2015-10-27 – 2016-01-28 · Diabetes
What this study did
NCT02328040 · Albert Einstein College of Medicine
2014-09 – 2016-01 · Diabetes Mellitus, Type 1
What this study did
NCT00652288 · Yale University
2007-04 – 2011-09 · Diabetes Mellitus, Type I
What this study did
NCT01125553 · Novo Nordisk A/S
2010-05 – 2010-08 · Diabetes, Healthy
What this study did
NCT00979875 · Halozyme Therapeutics
2009-09 – 2010-05 · Healthy
What this study did
NCT00992537 · Novo Nordisk A/S
2009-10 – 2010-01 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00993096 · Novo Nordisk A/S
2009-09 – 2009-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01868581 · Novo Nordisk A/S
2008-05 – 2008-08 · Diabetes, Healthy
What this study did
NCT00969592 · Profil Institut für Stoffwechselforschung GmbH
2007-11 – 2008-06 · Diabetes
What this study did
NCT01530048 · Novo Nordisk A/S
2006-03 – 2006-05 · Diabetes, Healthy
What this study did
Phase 4 (72)
Type 1 Diabetes
NCT03328845 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2017-01-20 – 2021-11-20 · Type 1 Diabetes Mellitus
What this study did
NCT04409587 · Mountain Diabetes and Endocrine Center
2018-04-12 – 2020-11-01 · Type1 Diabetes Mellitus
What this study did
NCT03987191 · University of Colorado, Denver
2020-01-10 – 2020-10-08 · Type 1 Diabetes
What this study did
NCT02192450 · Nordsjaellands Hospital
2015-01 – 2019-02-28 · Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia, Recurrent Severe Hypoglycaemia
What this study did
NCT03260868 · Sanofi
2017-09-19 – 2018-11-22 · Type 1 Diabetes Mellitus
What this study did
NCT02685449 · Medical University of Warsaw
2016-02 – 2018-08 · Diabetes type1
What this study did
NCT02276859 · Medical University of Warsaw
2014-10 – 2015-09 · Type 1 Diabetes
What this study did
NCT01526733 · Halozyme Therapeutics
2011-12 – 2013-09 · Type 1 Diabetes Mellitus
What this study did
NCT01678235 · Medical University of Warsaw
2011-09 – 2012-09 · Type 1 Diabetes Mellitus
What this study did
NCT00346996 · Lise Tarnow
2007-05 – 2012-08 · Type 1 Diabetes
What this study did
NCT00913497 · Corewell Health West
2009-06 – 2012-01 · Type 1 Diabetes Mellitus
What this study did
NCT00505882 · University of Texas Southwestern Medical Center
2007-07 – 2008-12 · Type 1 Diabetes
What this study did
NCT00461331 · Tulane University Health Sciences Center
2004-10 – 2008-08 · Type 1 Diabetes Mellitus
What this study did
NCT00509925 · Novo Nordisk A/S
2007-07 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00497536 · University of Aarhus
2007-07 – 2008-07 · Type 1 Diabetes Mellitus
What this study did
NCT00117780 · Novo Nordisk A/S
2005-06 – 2006-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00145353 · Odense University Hospital
2004-11 – 2006-06 · Type 1 Diabetes Mellitus
What this study did
NCT00365170 · Novo Nordisk A/S
2002-09 – 2005-04 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00571935 · Novo Nordisk A/S
2003-08 – 2004-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01467141 · Novo Nordisk A/S
2002-06-19 – 2003-10-15 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00597233 · Novo Nordisk A/S
2002-10 – 2002-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06127433 · Sun Yat-sen University
2023-03-07 – 2024-12-30 · Insulin Pump,Continuous Glucose Monitoring Technology
What this study did
NCT04538352 · The Cleveland Clinic
2021-01-18 – 2023-11-01 · Type 2 Diabetes
What this study did
NCT03336528 · Emory University
2018-01-02 – 2021-03-01 · Type 2 Diabetes
What this study did
NCT02408120 · Emory University
2015-10 – 2019-12-11 · Diabetes Mellitus, Type 2
What this study did
NCT01966978 · University of Texas Southwestern Medical Center
2014-11 – 2017-12 · Diabetes Mellitus, Type 2, Diabetes
What this study did
NCT02453685 · Novo Nordisk A/S
2015-08-31 – 2016-09-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03226210 · Nanjing First Hospital, Nanjing Medical University
2015-02-01 – 2016-07-01 · Diabetes Mellitus, Type 2
What this study did
NCT00821795 · Dennis G. Karounos, M.D.
2009-03-11 – 2013-04-23 · Type 2 Diabetes Mellitus
What this study did
NCT00942318 · University Hospital, Toulouse
2009-03 – 2013-02 · Type 2 Diabetes Mellitus
What this study did
NCT01407289 · Medical University of Graz
2011-06 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01165684 · Novo Nordisk A/S
2010-10 – 2012-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00771693 · Karolinska Institutet
2007-05 – 2011-07 · Type 2 Diabetes Mellitus, Postprandial Hyperglycemia
What this study did
NCT00906529 · University of Texas Southwestern Medical Center
2009-05 – 2011-03 · Type 2 Diabetes
What this study did
NCT01293396 · Medical University of Graz
2010-06 – 2011-03 · Type 2 Diabetes
What this study did
NCT00998335 · University of Florida
2007-06 – 2010-02 · Type 2 Diabetes
What this study did
NCT00591227 · Rush University Medical Center
2008-05 – 2009-07 · Type 2 Diabetes Mellitus
What this study did
NCT00747409 · Munich Municipal Hospital
2004-07 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
NCT00537303 · Novo Nordisk A/S
2007-10 – 2009-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00590226 · Emory University
2006-12 – 2008-04 · Type 2 Diabetes
What this study did
NCT00121966 · Odense University Hospital
2003-01 – 2007-07 · Type 2 Diabetes Mellitus
What this study did
NCT00274274 · Novo Nordisk A/S
2005-09 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00282451 · Novo Nordisk A/S
2006-02 – 2006-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00101751 · Novo Nordisk A/S
2004-10 – 2006-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00494988 · Novo Nordisk A/S
2004-12 – 2006-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00254085 · University Hospital, Gentofte, Copenhagen
2005-03 – 2006-03 · Type 2 Diabetes
What this study did
Early phase / not applicable (26)
Type 1 Diabetes
NCT06532461 · Steno Diabetes Center Copenhagen
2024-07-20 – 2026-12-31 · Type 1 Diabetes
What this study did
NCT04200313 · Jaeb Center for Health Research
2020-03-31 – 2022-01-14 · Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT04031599 · Institut de Recherches Cliniques de Montreal
2020-07-10 – 2021-12-14 · Type 1 Diabetes
What this study did
NCT04055480 · University of Cambridge
2019-08-10 – 2020-08-30 · Type 1 Diabetes
What this study did
NCT04112069 · Massachusetts General Hospital
2018-07-09 – 2018-11-19 · Type1 Diabetes Mellitus
What this study did
NCT02824510 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2014-08 – 2017-01 · Type 1 Diabetes
What this study did
NCT01621776 · University of Florida
2011-06 – 2012-08 · Type 1 Diabetes
What this study did
NCT01223560 · Hvidovre University Hospital
2009-10 – 2010-05 · Type 1 Diabetes
What this study did
NCT00428207 · Joslin Diabetes Center
2007-02 – 2008-08 · Type 1 Diabetes Mellitus
What this study did
NCT00283218 · University of Aarhus
2006-01 – 2006-08 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT07652528 · Hallym University
2026-08 – 2028-12 · Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
What this study did
NCT05417841 · Beijing Hospital
2023-03-23 – 2025-08-15 · Type 2 Diabetes Mellitus
What this study did
NCT01588743 · Li Guangwei
2008-10 – 2012-12 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07875803 · Zhuhai United Laboratories Co., Ltd.
2026-10-20 – 2027-02-28 · Pharmacokinetics and Pharmacodynamics
What this study did
NCT07600944 · Zhuhai United Laboratories Co., Ltd.
2026-05-06 – 2026-07-03 · Pharmacokinetics and Pharmacodynamics
What this study did
NCT04184466 · Geropharm
2018-10-18 – 2018-12-19 · Clamp Study
What this study did
NCT01149005 · Hadassah Medical Organization
2010-06 – 2015-12 · Cystic Fibrosis, Impaired Glucose Tolerance, Pulmonary Exacerbation
What this study did
NCT01947556 · University Medical Center Nijmegen
2014-03 – 2014-11 · Diabetes Mellitus
What this study did
NCT02144441 · University of Pennsylvania
2014-06 – 2014-10 · Diabetes Mellitus
What this study did
NCT01933490 · University of Minnesota
2013-08 – 2014-08 · Hyperinsulinemic Hypoglycemia
What this study did
NCT00625781 · Region Örebro County
2008-02 – 2013-12 · Impaired Glucose Tolerance, Fetal Macrosomia
What this study did
NCT01702311 · Emory University
2012-05 – 2013-12 · Diabetes
What this study did
NCT00353431 · University Hospital, Basel, Switzerland
2006-12 – 2010-10 · Hyperglycemias
What this study did
NCT00920725 · Rush University Medical Center
2005-01 – 2007-12 · Diabetic Ketoacidosis
What this study did
NCT00410033 · Novo Nordisk A/S
1989-12 – 2006-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00206206 · Atlantic Health System
started 2005-07 · Hyperglycemia
What this study did
Used as active comparator (48)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (19)
Type 1 Diabetes
NCT01445951 · Mannkind Corporation
2011-09 – 2013-06 · Type 1 Diabetes Mellitus
What this study did
NCT00322257 · Novo Nordisk A/S
2006-05-01 – 2008-04-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT05767255 · Hospital Universitario San Ignacio
2022-12-01 – 2023-08-30 · Diabetes Mellitus, Type 2 Treated With Insulin
What this study did
NCT03689374 · Novo Nordisk A/S
2018-10-01 – 2021-02-22 · Diabetes Mellitus, Type 2
What this study did
NCT03211858 · Sanofi
2017-08-02 – 2019-01-12 · Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
What this study did
NCT02420262 · Novo Nordisk A/S
2015-07-26 – 2016-10-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01196104 · Mannkind Corporation
2010-09 – 2012-03 · Type 2 Diabetes
What this study did
NCT00184600 · Novo Nordisk A/S
2004-11 – 2009-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00434954 · AstraZeneca
2007-02 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
NCT00082407 · AstraZeneca
2003-11 – 2008-07 · Diabetes Mellitus, Type 2
What this study did
NCT00331604 · Novo Nordisk A/S
2006-08-31 – 2008-05-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00472953 · Novo Nordisk A/S
2007-05-15 – 2008-03-05 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease
What this study did
NCT00523042 · Novo Nordisk A/S
2007-08-30 – 2008-02-28 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
What this study did
Other / comorbidity
NCT03737240 · Emory University
2019-01-15 – 2022-07-08 · Diabetes Mellitus
What this study did
NCT01134107 · Eli Lilly and Company
2010-11 – 2011-12 · Diabetes Mellitus, Type 1
What this study did
NCT01109316 · Eli Lilly and Company
2010-04 – 2011-08 · Diabetes Mellitus, Type 1
What this study did
Phase 2/3 (3)
Type 2 Diabetes
NCT03430856 · Biocon Limited
2017-12-26 – 2019-02-20 · Type2 Diabetes Mellitus
What this study did
Other / comorbidity
Phase 2 (4)
Type 1 Diabetes
NCT00850161 · CPEX Pharmaceuticals Inc.
2009-07 – 2010-09 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT07387003 · Gan & Lee Pharmaceuticals.
2026-04-10 – 2027-09-23 · Type 2 Diabetes (T2DM)
What this study did
NCT06199505 · Gan and Lee Pharmaceuticals, USA
2023-11-21 – 2024-07-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT00624767 · Nastech Pharmaceutical Company, Inc.
2008-03 – 2008-05 · Diabetes Mellitus
What this study did
Phase 1/2 (1)
Type 1 Diabetes
NCT03981627 · Adocia
2019-06-06 – 2020-06-27 · Type 1 Diabetes Mellitus
What this study did
Phase 1 (6)
Type 1 Diabetes
NCT03449433 · Eli Lilly and Company
2018-03-15 – 2018-08-14 · Diabetes Mellitus, Type 1
What this study did
NCT02938572 · Novo Nordisk A/S
2016-10-19 – 2017-07-04 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT03202875 · Sanofi
2012-11-14 – 2012-12-28 · Type 1 Diabetes
What this study did
Other / comorbidity
NCT06492226 · Xentria, Inc.
2024-07-30 – 2024-10-31 · Healthy Participants
What this study did
NCT05719961 · Jiangsu HengRui Medicine Co., Ltd.
2023-01-05 – 2023-07-30 · Diabetes
What this study did
Phase 4 (10)
Type 2 Diabetes
NCT03660553 · University of Miami
2018-10-10 – 2022-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT04120623 · Nanjing First Hospital, Nanjing Medical University
2019-10-01 – 2020-02-28 · Type 2 Diabetes Mellitus
What this study did
NCT02467920 · Huazhong University of Science and Technology
2015-08 – 2017-12 · Type 2 Diabetes Mellitus
What this study did
NCT00965549 · Sanofi
2009-07 – 2012-12 · Diabetes Mellitus, Type 2
What this study did
NCT00657943 · Steno Diabetes Center Copenhagen
2008-04 – 2012-12 · Type 2 Diabetes, Atherosclerosis, Arteriosclerosis
What this study did
NCT01079364 · Sanofi
2010-01 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01417897 · ikfe-CRO GmbH
2011-09 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT00467649 · AstraZeneca
2007-05 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT04012138 · Nantes University Hospital
2019-12-20 – 2025-12-20 · Hyperkalemia
What this study did
Early phase / not applicable (5)
Type 1 Diabetes
NCT06948760 · Mark D. DeBoer, MD, MSc., MCR
2025-07-23 – 2026-03-10 · Type 1 Diabetes
What this study did
NCT04965051 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-08 – 2023-12 · Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
What this study did
Type 2 Diabetes
NCT03987308 · Beijing Hospital
2019-07-02 – 2025-12 · Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
What this study did
NCT02887625 · Dr. Muhammad Abdulghani
2015-02 – 2017-05 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT00574405 · Arkansas Children's Hospital Research Institute
2005-04 – 2011-03 · Diabetes Mellitus
What this study did
Studied as part of a combination product (3)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (2)
Type 2 Diabetes
NCT01520753 · Novo Nordisk A/S
1999-03 – 1999-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01467323 · Novo Nordisk A/S
1998-04 – 1998-09 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT07173712 · Yanbing Li
2026-03-15 – 2027-12-31 · Type 2 Diabetes
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 1 Diabetes
Phase 1 (1)
Other / comorbidity
NCT05946785 · Anna Stanhewicz, PhD
2023-07-01 – 2027-06-01 · Gestational Diabetes, Vascular Endothelial Function
What this study did
Phase 4 (3)
Type 2 Diabetes
NCT02556918 · Emory University
2016-01 – 2018-11-06 · Hyperglycemia
What this study did
Other / comorbidity
NCT02741687 · Emory University
2016-06 – 2017-04 · Hyperglycemia
What this study did
NCT02443402 · Emory University
2016-01 – 2016-12 · Coronary Artery Disease
What this study did
Early phase / not applicable (3)
Type 1 Diabetes
NCT05221359 · Defymed
2022-05-05 – 2027-04 · Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
What this study did
NCT01531855 · Northumbria University
2012-02 – 2012-08 · Type 1 Diabetes
What this study did
Other / comorbidity
NCT00464854 · Assaf-Harofeh Medical Center
2005-07 – 2006-09 · Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Aspart (NovoLog): this drugApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
THDB0206Phase 3PeptideInsulin receptorPartial signalNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninPartial signal
NCT05731544: icovamenib showed a mean reduction in HbA1c of 0.36% (p=0.022). The strongest performing arm was Arm B (icovamenib dosed at 100mg QD for 12 weeks) with a mean HbA1c reduction of 0.5% (p=0.012).
Insulin Aspart (AT278)Phase 1PeptideInsulin receptorPartial signal
NCT05754424: Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001).

Large race: only the 69 furthest-along competitors are listed; 81 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow NovoLog (insulin aspart) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicableType 1 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06532461 · CT.gov ↗
What to watch
2027 (2)
February 2027 (2)
Phase 1Healthy ParticipantsRecruiting
Est. primary completion 2027-02-02 · NCT07918898 · CT.gov ↗
What to watch
Early phase / not applicablePharmacokinetics and PharmacodynamicsNot yet recruiting
Est. primary completion 2027-02-28 · NCT07875803 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2028-06 · NCT07652528 · CT.gov ↗
What to watch

See the full readout calendar ↗